The Hematocrit Test Devices Market was valued at US$ 5.1 billion in 2022 and is estimated to grow at a CAGR of 3.4% from 2023 ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea ...

Anemia Deficiency in the concentration of erythrocytes and/or hemoglobin concentration; further defined as a hematocrit or hemoglobin greater than 2 standard deviations below the mean for age and ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class ...